The vast majority of biotechnology companies have two choices in the current environment: remake themselves proactively or wait until they're forced to the wall.

Repligen Corp. made the decision to regroup sooner rather than later, announcing a restructuring and reorganization to reduce expenses, focus resources on the clinical development of its three lead product candidates, and seek strategic partners for all three products.